Dr. Armin Ghobadi, M.D.
Claim this profileWashington University School of Medicine
Studies Acute Myeloid Leukemia
Studies Lymphoma
30 reported clinical trials
43 drugs studied
Area of expertise
1Acute Myeloid Leukemia
CD7 positive
FLT3 negative
CEBPA positive
2Lymphoma
CD7 positive
any
anti-CD20 monoclonal antibody
Affiliated Hospitals
Clinical Trials Armin Ghobadi, M.D. is currently running
CIML NK Cell Therapy
for Acute Myeloid Leukemia
This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).
Recruiting1 award Phase 2
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
More about Armin Ghobadi, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 30 trials as a Principal Investigator · 14 Active Clinical TrialsTreatments Armin Ghobadi, M.D. has experience with
- Cytokine Induced Memory-like NK Cell Adoptive Therapy
- Isatuximab
- Nivolumab
- WU-CART-007
- Mosunetuzumab
- Tabelecleucel
Breakdown of trials Armin Ghobadi, M.D. has run
Acute Myeloid Leukemia
Lymphoma
Leukemia
Graft-versus-Host Disease
- Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
- ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
- Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Armin Ghobadi, M.D. specialize in?
Armin Ghobadi, M.D. focuses on Acute Myeloid Leukemia and Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved CD7 positive patients, or patients who are FLT3 negative.
Is Armin Ghobadi, M.D. currently recruiting for clinical trials?
Yes, Armin Ghobadi, M.D. is currently recruiting for 12 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Armin Ghobadi, M.D. has studied deeply?
Yes, Armin Ghobadi, M.D. has studied treatments such as Cytokine Induced Memory-like NK Cell Adoptive Therapy, Isatuximab, Nivolumab.
What is the best way to schedule an appointment with Armin Ghobadi, M.D.?
Apply for one of the trials that Armin Ghobadi, M.D. is conducting.
What is the office address of Armin Ghobadi, M.D.?
The office of Armin Ghobadi, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.